RG6035 / Roche - LARVOL DELTA

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. (PubMed, CNS Drugs) - "Initial apparent success with rituximab in MS and neuromyelitis optica spurred development of the anti-CD20 monoclonal antibody (mAb) therapies ocrelizumab, ofatumumab, and ublituximab as well as the anti-CD19 mAb inebilizumab...Glycoengineering of the mAbs ublituximab and inebilizumab enhances ADCC and can overcome the reduced responses to mAb-mediated B-cell depletion associated with certain genetic polymorphisms. Other strategies for therapeutic targeting of CD20, including brain shuttle antibodies (e.g., RO7121932), bispecific antibodies, chimeric antigen receptor T-cell therapies, and antibody-drug conjugates, are in active clinical development and may be future treatment approaches in MS and other B-cell-mediated autoimmune diseases."

Journal • Review • CNS Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Multiple Sclerosis • Neuromyelitis Optica Spectrum Disorder • Oncology • Rare Diseases

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis. (clinicaltrials.gov) - P1 | N=129 | Recruiting | Sponsor: Hoffmann-La Roche | N=63 ➔ 129 | Trial completion date: Mar 2025 ➔ Dec 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis (clinicaltrials.gov) - P1 | N=63 | Recruiting | Sponsor: Hoffmann-La Roche

New P1 trial • CNS Disorders • Multiple Sclerosis